Immunotherapy of cancer with allogeneic lymphocytes
OwnerShimon Slavininventor
Life of this patent
Estimating the term…
Abstract
Methods have been discovered for treating minimal residual disease following removal of most or a substantial fraction of malignant cells from a cancer patient. An autologous stem cell transplant is performed on the patient. Following partial hematopoiesis recovery, the patient is infused with allogeneic peripheral blood lymphocytes, either alone or in combination with in vivo or in vitro cytokine. The infused allogeneic lymphocytes engender an anti-malignant cell response and can be instrumental in prevention of disease relapse.
Claims19
A method of treating a human cancer patient, said patient having undergone a malignant cell debulking procedure and being at risk for disease relapse due to a population of residual malignant cells that may remain viable in said patient following said debulking procedure, comprising:
- a) providing a sample of stem cells from said patient, said sample being suitable for autologous transplantation into said patient;
- b) performing an autologous transplant of said patient with said sample;
- c) monitoring said patient until said patient is partially hematopoiesis recovered but is not fully immune-reconstituted;
- d) administering to said patient an HLA-compatible, allogeneic peripheral blood leukocyte preparation having lymphocytes, in a regimen that causes a clinically significant graft-versus-malignant cell response;
- and
- e) monitoring said patient for levels of malignant cells deriving from said population.
A method of treating a human cancer patient, said patient having undergone a malignant cell debulking procedure and being at risk for disease relapse due to a population of residual malignant cells that may remain viable in said patient following said debulking procedure, comprising:
- a) providing a sample of stem cells from said patient, said sample being suitable for autologous transplantation into said patient;
- b) performing an autologous transplant of said patient with said sample;
- c) monitoring said patient until said patient is partially hematopoiesis recovered but is not fully immune-reconstituted;
- d) administering to said patient an HLA-compatible, allogeneic peripheral blood leukocyte preparation having lymphocytes, in a regimen that causes a mild graft-versus-host response;
- and
- e) monitoring said patient for levels of malignant cells deriving from said population.
Dependencies are inferred from the claim text.